Abstract | PURPOSE OF REVIEW: Normal B cells that have failed to productively rearrange immunoglobulin V region genes encoding a functional B-cell receptor (BCR) are destined to die. Likewise, the majority of B-cell malignancies remain dependent on functional BCR signaling, whereas in some subtypes BCR expression is missing and, apparently, counterselected. Here, we summarize the recent experimental evidence for the importance of BCR signaling and clinical concepts to target the BCR pathway in B-cell leukemia and lymphoma. RECENT FINDINGS: SUMMARY:
|
Authors | Maike Buchner, Markus Müschen |
Journal | Current opinion in hematology
(Curr Opin Hematol)
Vol. 21
Issue 4
Pg. 341-9
(Jul 2014)
ISSN: 1531-7048 [Electronic] United States |
PMID | 24811161
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Receptors, Antigen, B-Cell
|
Topics |
- Animals
- Cell Transformation, Neoplastic
(genetics, metabolism)
- Humans
- Leukemia, B-Cell
(drug therapy, genetics, metabolism)
- Lymphoma, B-Cell
(drug therapy, genetics, metabolism)
- Molecular Targeted Therapy
- Receptors, Antigen, B-Cell
(metabolism)
- Signal Transduction
(drug effects)
|